CoChat

A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy

Durnwald, Celeste P., Landon, Mark B. · 2008 · The Journal of Maternal-Fetal & Neonatal Medicine

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To describe perinatal outcomes of women with pregestational diabetes treated with short-acting, regular insulin and the short-acting insulin analogue, lispro. STUDY DESIGN: This was a prospective observational study of women with pregestational diabetes maintained on short-acting insulin regimens over a 3-year period. Clinical characteristics, aspects of diabetic therapy, and perinatal/neonatal outcomes were collected. RESULTS: Of 107 women, 49 were maintained on regular insulin and 58 utilized the insulin analogue, lispro. Frequency of type 1 diabetes, maternal age, overweight/obese pregravid body mass index (> or =25 kg/m2), preexisting hypertension, and presence of vascular disease were similar between groups. Women treated with lispro had a longer duration of diabetes (11.4 vs. 8.3 years, p = 0.04). Glycemic control was improved in women managed with lispro compared to regular insulin (HgbA1c 5.9 vs. 6.7, p = 0.009). Total insulin requirements were lower in the lispro group in the first (0.58 vs. 0.79 units/kg, p = 0.02), second (0.75 vs. 1.10 units/kg, p = 0.002), and third (0.98 vs. 1.25 units/kg, p = 0.03) trimesters of pregnancy. Mean infant birth weight was greater in the lispro group, whereas the rate of large for gestational age infants and ponderal indices were similar between groups. Malformation rate, gestational age at delivery, neonatal intensive care unit admission, neonatal length of stay, rates of respiratory distress syndrome, and hypoglycemia were similar. CONCLUSIONS: Women treated with lispro demonstrated improved glycemic control and lower total insulin requirements during pregnancy compared to those receiving regular insulin. Perinatal outcomes were similar between women treated with both types of insulin.

Overview

Integrity signals

Registry

Crossref · 10.1080/14767050802022797

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. Cypryk K, 2004, Med Sci Monit, 10, 29

Cited by

See all 64

Metadata

Authors
Durnwald, C. P., & Landon, M. B.
Affiliations
The Ohio State University (US)
Corresponding author
Durnwald, Celeste P.
Venue
The Journal of Maternal-Fetal & Neonatal Medicine
Published
2008-01
Volume
21
Issue
5
Pages
309-313
ISSN
  • 1476-4954 (ISSN-L)
  • 1476-7058
OpenAlex
W2008468334
Cited by
61
References
18
Citations by year
2026: 1 · 2021: 4 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 4 · 2013: 8 · 2012: 5
FWCI
5.35
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Maternal-Fetal & Neonatal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin lispro, regular insulin, insulin analogues, pregestational diabetes, type 1 diabetes, type 2 diabetes, diabetes in pregnancy, glycemic control, insulin requirement, perinatal outcomes, birth weight, large for gestational age, neonatal outcomes
MeSH terms
Adult, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Pregnancy, Pregnancy in Diabetics, Pregnancy Outcome, Prospective Studies, Treatment Outcome, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. https://app.cochat.ai/papers/10.1080/14767050802022797
The paper
Durnwald, C. P., & Landon, M. B. (2008). A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.1080/14767050802022797

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.